ORIGINAL ARTICLE

The Risk of Rosacea According to Chronic Diseases and Medications: A 5-Year Retrospective, Multi-Institutional Case-Control Study

Jee Hee Son*, Bo Young Chung*, Min Je Jung, Yong Won Choi, Hye One Kim, Chun Wook Park

Department of Dermatology, Hallym University Kangnam Sacred Heart Hospital, College of Medicine, Hallym University, Seoul, Korea

Background: Rosacea is associated with chronic systemic disease. However, research is lacking in Asian countries. Objective: To evaluate the association between rosacea and cardiovascular diseases (CVDs) related systemic comorbidities, and the use of antihypertensive and antihyperlipidemic drugs in Korea. Methods: A five-year retrospective study, using hospital database, was conducted in five medical centers for five years. Totally 1,399,528 patients were evaluated. Results: The overall frequency for diagnosed rosacea was 0.18% over five years (2,536 rosacea patients). Patients with diabetes and patients with dyslipidemia were more likely to have rosacea (odd ratio [OR] 2.724, 95% confidence interval [CI] 1.295 ~ 5.730, p = 0.016; OR 1.788, 95% CI 1.445 ~ 2.212, p < 0.001). Patients with CVD were less likely to have rosacea (OR 0.431, 95% CI 0.244 ~ 0.760, p = 0.003). Patients with α-blocker prescriptions and patients with β-blocker prescriptions showed a tendency diagnosed with rosacea frequently (OR 1.963, 95% CI 1.200 ~ 3.212, p = 0.006; OR 3.939, 95% CI 3.512 ~ 4.419, p < 0.001). Patients with [beta]-hydroxy-[beta]-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor, and those with tizane, were prone to have rosacea (OR 1.599, 95% CI 1.390 ~ 1.839, p < 0.001; OR 1.660, 95% CI 1.056 ~ 2.609, p = 0.026). As adjusted results, among the patients who took HMG-CoA reductase inhibitor without dyslipidemia, rosacea was less likely to be diagnosed (OR 0.780, 95% CI 0.620 ~ 0.982, p = 0.034).

Conclusion: Rosacea is associated with chronic diseases and drugs. (Ann Dermatol 30(6) 676 ~ 687, 2018)

Keywords: Antihypertensive agents, Cardiovascular diseases, Chronic disease, Hyperlipidemias, Rosacea

INTRODUCTION

Rosacea is a chronic inflammatory skin disease and symptoms present in variable degrees of facial erythema, telangiectasias, papules, and pustules. Although the exact pathophysiology of rosacea has not been established yet, vascular reactivity, sun exposure, inflammations, microorganisms such as Helicobacter pylori, Demodex folliculorum, Staphylococcus epidermidis and Bacillus oleronius, and neuro-psychogenic factor seem to be involved. Besides a variety of other suggested mechanisms about pathogenesis, evidence points to a key role in rosacea of neurovascular dysregulation and neurogenic inflammation in the vasodilative pathomechanism. The proposed pathogenic factors have not yet been proven. Recently, associations between various chronic inflammatory diseases,
such as rheumatoid arthritis (RA) and psoriasis, with cardiovascular disease (CVD) were reported. Systemic studies to show the associations of rosacea with extracutaneous diseases are few. Rosacea can appear in all ethnic groups but previous studies reported that rosacea is less common among Asians or Mongoloids. It might imply a different pathophysiology related to genetic background or genetic susceptibility. Because most previous studies tried to reveal associations between CVD and rosacea among Caucasians, it is needed and meaningful to determine the relationship between CVD, its drugs, and rosacea among Asians.

Therefore, we tried to investigate a group of rosacea patients among the patients who had risk factors of CVD and who were prescribed drugs for chronic systemic disease in South Korea.

**MATERIALS AND METHODS**

**Patient collective and data source**

We conducted a five-year retrospective, multi-institutional pooled analysis in five hospitals. A total of 1,399,528 patients in Hallym, Doangtan, Hangang, Chuncheon, and Kangnam Sacred Heart Hospitals between January 2011 and December 2015 were included. Among them, we selected rosacea patients from the hospital database, a program named Clinical Data Warehouse (CDW) with the International Classification of Diseases (ICD) diagnostic codes for “rosacea” (L711, L718 or L719). The extracted rosacea population consisted of 2,536 patients who firstly recorded the ICD codes for rosacea as new patient on dates between study periods.

**Study design and clinical data**

We obtained patients with cardiovascular risk factors from the CDW database. We used ICD codes, including I101 I109 hypertension, E780 E785, E788 dyslipidemia or hyperlipidemia, I250 I259 atherosclerotic heart disease (chronic ischemic heart disease), I1630 I1639 cerebral infarction, E10 E14 diabetes, and I740 I749 arterial embolism and thrombosis (peripheral arterial occlusive disease). We collected patients’ data including demographic data (age at diagnosis, gender) and medical history (comorbidities which are the above-mentioned diseases extracted as ICD code, disease type and duration). After that, among them, patients diagnosed with rosacea were extracted again. The time at which diagnosed with rosacea was set up as an index date. Only those patients diagnosed with known systemic or cardiovascular disease before the index date were included.

Drug prescriptions of patients are generated electronically via computer, ensuring a virtually complete drug history. All the target prescribed drugs were investigated by subgroups such as antihypertensive drugs and antihyperlipidemic drugs. Table 1 shows which drugs we used to extract data. We extracted rosacea patients again just as above. Only patients prescribed certain drugs before the index date were included.

To consider the interactive effect of disease and drugs, subdivided analysis was done. Each disease and a drug were paired (e.g., a hypertension and antihypertensive drug, hypertension and aspirin, CVD and aspirin, dyslipidemia and [beta]-hydroxy-[beta]-methylglutaryl coenzyme A [HMG-CoA] reductase inhibitor), with concern that each other acts as a confounding factor.

To establish the frequency of the diagnosed rosacea in the population, we assessed the number of rosacea patients during five years by year and by sex.

The protocol was approved by the Institutional Review Board of Hallym University Kangnam Sacred Heart Hospital (IRB no. 2016-06-77).

**Statistical analysis**

We estimated the frequency of diagnosed rosacea using the Poisson regression analysis. We use the genlin command to estimate a Poisson regression model. We have one continuous predictor and one categorical predictor. The factor, categorical variable was sex and cell covariate, continuous variable was year. The “cases of diagnosed rosacea” is the dependent variable, whereas “sex” is nominal independent variable. The probability distribution is “Poisson” and the link function is the natural logarithm. The logged variable, “Ln_ total (total number of patients)”, is used as the offset variable. Using the chi-square test, the proportion of rosacea-exhibiting and rosacea-free patients for each disease and each drug was calculated. The significance level set for all analyses was $p<0.05$. All statistical analyses were conducted using PASW Statistics 18 (IBM Co., Armonk, NY, USA).

**RESULTS**

**Rosacea patient characteristics**

The study population encompassed 2,536 patients with rosacea, of whom 1,745 patients (68.81%) were female. A total of 1,399,528 patients visited hospitals during the five target years. The vast majority (2,151 or 84.81%) of patients with rosacea were above the age of 30 years at the index date. Their average age was $47.21 \pm 15.01$ years.
**Table 1.** Classification of drugs

| Classification | Detailed classification | Specific drugs |
|----------------|-------------------------|----------------|
| **β-Blocker**  | β₁ and β₂ blocker       | Propranolol 10 mg, 40 mg (Indenol tab Dongkwang Pharm, Seoul, Korea) |
|                | β₁ selective blocker     | Atenolol 50 mg (SCD Atenolol tab Sam Chun Dang Pharm, Seoul, Korea) |
|                |                         | Nebivolol hydrochloride 2.725 mg (Nebistol tab Elyson pharmaceutical, Hwaseong, Korea) |
|                |                         | Nebivolol 5 mg (Nebiret tab SAM-OH Pharm, Seoul, Korea) |
|                |                         | Bisoprolol 2.5 mg, 5 mg (Concor tab Merck Korea, Seoul, Korea) |
|                | Non selective β and α₁-blocker | Carvedilol 8 mg, 16 mg, 32 mg, 64 mg (Dilatrend SR Cap Chong Kun Dang Pharm, Seoul, Korea) |
|                |                         | Carvedilol 6.5 mg, 12.5 mg, 25 mg (Dilatrend tab Chong Kun Dang Pharm, Seoul, Korea) |
| **α-Blocker**  | α₁-blocker              | Doxazosin 1 mg, 2 mg (Cadil tab Binex, Incheon, Korea) |
|                |                         | Doxazosin 4 mg (Cardura-XL tab Pfizer Korea, Seoul, Korea) |
|                |                         | Terazosin 2 mg (Bepanti tab Shin Poong Pharm, Ansan, Korea) |
|                |                         | Terazosin 5 mg (Hytrin tab IL-YANG Pharm, Yongin, Korea) |
| **Diuretics**  | Thiazide                 | Hydrochlorothiazide 25 mg (Dichlozid tab Yuhan Corporation, Seoul, Korea) |
|                | Thiazide-like            | Indapamide 1.5 mg (Fludex SR tab Servier Korea, Seoul, Korea) |
|                | Carbonic anhydrase inhibitors | Acetazolamide 250 mg (Acetazol tab Hanlim Pharm, Seoul, Korea) |
|                | Loop diuretics           | Furosemide 40 mg (Lasix tab Han Dok Pharm, Seoul, Korea) |
|                |                         | Torasemide 5 mg (Torsem tab Hanmi Pharm, Seoul, Korea) |
|                | Potassium sparing diuretics | Amilone 5 mg (Amilo tab Kuhnil Pharm, Seoul, Korea) |
|                | Selective Alginine Vasopessin antagonist | Tolvaptan Spray Dry Powder 15 mg, 30 mg (Samsca tab Korea Otsuka Pharm, Seoul, Korea) |
| **Calcium channel blocker (CCB)** | Dihydropyridines | Nifedipine 30 mg, 60 mg (Adalat OROS tab Bayer Korea, Seoul, Korea) |
|                |                         | Nifedipine 40 mg (Nifedipine CR tab Kyung Poong Pharma, Seoul, Korea) |
|                |                         | Amlodipine besylate 5 mg, 10 mg (Norvasc tab Pfizer Korea, Seoul, Korea) |
|                |                         | Benidipine HCl 4 mg, 8 mg (Coniel tab Myung In Pharm, Seoul, Korea) |
|                |                         | Enalidipine hydrochloride 20 mg, 40 mg (Finte tab Green Cross Corporation, Seoul, Korea) |
| **Nondihydropyridines-CCB** |                         | Cilnidipine 10 mg (Cinalong tab Boryung Pharm, Seoul, Korea) |
| **Angiotensin-converting enzyme inhibitor** |                         | Diltiazem 180 mg (Diltex SR cap Alvogen Korea, Seoul, Korea) |
|                |                         | Verapamil 240 mg (Isoptin SR tab Ilsung Pharm, Seoul, Korea) |
| **Angiotensin II receptor blocker** |                         | Candesartan 16 mg (Candesart tab Chong Kun Dang Pharm, Seoul, Korea) |
| **HMG-CoA reductase inhibitor** |                         | Fimasartan K trihydrate 132.02 mg (Kanarb tab Boryung Pharm, Seoul, Korea) |
| **Fibrates**   |                         | Losartan potassium 100 mg (Cozaar tab MSD Korea, Seoul, Korea) |
|                |                         | Telmisartan 40 mg (Micardis tab Boehringer Ingelheim Korea, Seoul, Korea) |
| **Cholestyramine** |                         | Valsartan 160 mg (Diovan tab Norvatis Korea, Seoul, Korea) |
| **Aspirin**    |                         | Atorvastatin calcium 10 mg (Lipitor tab Pfizer Korea, Seoul, Korea) |
|                |                         | Fluvastatin 80 mg (Lescol XL SR tab Norvatis Korea, Seoul, Korea) |
|                |                         | Pitavastatin 2 mg (Livalo tab JW pharm, Seoul, Korea) |
|                |                         | Pravastatin 10 mg, 40 mg (Mevalotin tab CJ HealthCare, Seoul, Korea) |
|                |                         | Simvastatin 20 mg (Simvast CR tab Hanmi Pharm, Seoul, Korea) |
|                |                         | Micro-coating suspension Fenofibrate 160 mg (Lipidil Supra tab Green Cross Corporation, Seoul, Korea) |
|                |                         | Cholestyramine Resin 4 g/9 g (Questran Powder for Suspension Boryung Boryung Pharm, Seoul, Korea) |
| **HMG-CoA:** [β-hydroxy-β-methyl]glutaryl coenzyme A. | Aspirin enteric coated pellet 100 mg (Astrix cap Boryung Pharm, Seoul, Korea) |
|                |                         | Aspirin enteric coated 100 mg (Aspirin protect tab Bayer Korea, Seoul, Korea) |
The frequency of diagnosed rosacea in five hospitals in the last five years

The frequency of diagnosed rosacea in the study population was 0.18% (181.20 per 100,000) during the five years from 2011 to 2015. Fig. 1 shows changes in the frequency of diagnosed rosacea. It was higher in women (0.25%, 1,745/705,748) than in men (0.11%, 791/693,780). In women, it was 2.062 times significantly higher than in men (p<0.001). The frequency of diagnosed rosacea in each year did not differ significantly over the five years (p=0.132).

Risk of diagnosed rosacea according to chronic systemic diseases, as related to cardiovascular risk factors and prescribed drugs

Of the 1,399,528 patients, some were selected depending on their comorbidities and their prescribed drugs. Table 2 presents rosacea patients who were extracted in relation to chronic systemic diseases and prescribed drugs. Patients with diabetes (odd ratio [OR] 2.724, 95% confidence interval [CI] 1.295~5.730, p=0.016), and pa-

![Fig. 1. Changes in the frequency of diagnosed rosacea by sex in five medical centers for five years.](image1)

![Fig. 2. Risk of diagnosed rosacea according to chronic systemic diseases. IHD: ischemic heart disease, CVD: cardiovascular disease. *p<0.05.](image2)

| Variable               | Rosacea | Without rosacea | Total population (n) | p-value | 95% confidence interval | Odds ratio |
|------------------------|---------|-----------------|----------------------|---------|-------------------------|------------|
| Diabetes               | 7 (0.5) | 1,418 (99.5)    | 1,425                | 0.016*  | 1.295~5.730             | 2.724      |
| Hypertension           | 101 (0.2) | 46,503 (99.8)  | 46,604               | 0.073   | 0.987~1.470             | 1.205      |
| Cerebral infarction    | 12 (0.1) | 15,241 (99.9)  | 15,253               | 0.003** | 0.244~0.760             | 0.431      |
| PAOD                   | 0 (0)   | 33 (100)        | 33                   | 1.000   |                         |            |
| Dyslipidemia           | 88 (0.3) | 27,534 (99.7)  | 27,622               | 0.000***| 1.445~2.212             | 1.788      |
| IHD                    | 4 (0.2)  | 2,540 (99.8)    | 2,544                | 1.000   | 0.325~2.314             | 0.867      |
| a-Blocker              | 16 (0.4) | 4,504 (99.6)    | 4,520                | 0.006** | 1.200~3.212             | 1.963      |
| BB                     | 239 (0.5) | 52,582 (99.5)  | 52,821               | 0.000***| 3.512~4.419             | 3.939      |
| CCB                    | 65 (0.2) | 33,792 (99.8)  | 33,857               | 0.611   | 0.975~1.629             | 1.061      |
| Diuretics              | 60 (0.2) | 31,052 (99.8)  | 31,112               | 0.396   | 0.825~1.377             | 1.066      |
| ACEi                   | 15 (0.2) | 7,431 (99.8)    | 7,446                | 0.680   | 0.669~1.849             | 0.899      |
| ARB                    | 55 (0.2) | 23,350 (99.8)  | 23,405               | 0.058   | 0.998~1.704             | 0.767      |
| HMG-CoA reductase      | 186 (0.2) | 75,534 (99.8)  | 75,720               | 0.000***| 1.390~1.839             | 1.599      |
| inhibitor              |         |                 |                      |         |                         |            |
| Fibates                | 19 (0.3) | 6,323 (99.7)    | 6,342                | 0.026*  | 1.056~2.609             | 1.660      |
| Cholestyramine         | 0 (0)   | 153 (100)       | 153                  | 1.000   |                         |            |
| ASA                    | 69 (0.2) | 43026 (99.8)    | 43095                | 0.509   | 0.726~1.172             | 0.923      |

Values are presented as number (%). PAOD: peripheral arterial occlusive disease, IHD: ischemic heart disease, BB: β-blocker, CCB: calcium channel blocker, ACEi: angiotensin-converting-enzyme inhibitor, ARB: angiotensin II receptor blocker, HMG-CoA: [beta]-hydroxy-[beta]-methylglutaryl coenzyme A, ASA: aspirin. *p<0.05, **p<0.01, ***p<0.001.
tients with dyslipidemia (OR 1.788, 95% CI 1.445–2.212, \( p < 0.001 \)), were significantly more likely to have rosacea. Patients with hypertension was more likely to have rosacea, but this was not statistically significant (OR 1.205, 95% CI 0.987–1.470, \( p = 0.073 \)). Meanwhile, patients with cerebral infarction were statistically less prone to have rosacea (OR 0.431, 95% CI 0.244–0.760, \( p = 0.003 \)) (Fig. 2).

Patients with one or more recorded \( \alpha \)-blockers, and patients with \( \beta \)-blocker (BB) prescriptions, showed a significantly greater tendency to be diagnosed with rosacea compared with patients without such prescriptions (OR 1.963, 95% CI 1.200–3.212, \( p = 0.006 \); OR 3.939, 95% CI 3.512–4.419, \( p < 0.001 \)). Moreover, patients with HMG-CoA reductase inhibitor and patients with fibrate were significantly more prone to have rosacea (OR 1.599, 95% CI 1.390–1.839, \( p < 0.001 \); OR 1.660, 95% CI 1.056–2.609, \( p = 0.026 \)). Patients with calcium channel blocker (CCB, OR 1.061, 95% CI 0.975–1.629, \( p = 0.611 \)) and patients with diuretics (OR 1.066, 95% CI 0.825–1.377, \( p = 0.596 \)) were slightly more likely to have rosacea, but these were not statistically significant (Fig. 3).

**Risk of diagnosed rosacea according to antihypertensive or antihyperlipidemic drug subtypes**

The proportions of rosacea and rosacea-free patients for each antihypertensive or antihyperlipidemic drug are summarized in Table 3. Among the patients with one or more recorded BB \( \beta_1 \) and \( \beta_2 \) (OR 5.106, 95% CI 4.380–5.953, \( p < 0.001 \)), non-selective BB and \( \alpha_1 \)-blocker (OR 6.288, 95% CI 5.245–7.539, \( p < 0.001 \)), and \( \mathrm{V}_2 \) arginine vasopressin receptor antagonists (OR 11.430, 95% CI 1.584–83.201, \( p = 0.002 \)), rosacea was significantly more likely to be diagnosed (Fig. 4). No drugs showed a significant tendency for users less diagnosed with rosacea, compared

### Table 3. The risk of diagnosed rosacea according to classified drugs by subtypes

| Variable | Rosacea | Without rosacea | Total population (n) | \( p \)-value | 95% confidence interval | Odds ratio |
|----------|---------|------------------|----------------------|--------------|-------------------------|------------|
| Beta blockers, beta 1 and beta 2 | 177 (0.9) | 20,230 (99.1) | 20,407 | 0.000*** | 4.380–5.953 | 5.106 |
| Beta blockers, beta 1 selective | 37 (0.2) | 20,924 (99.8) | 20,961 | 0.876 | 0.704–1.347 | 0.974 |
| Non selective beta and alpha 1 blocker | 124 (1.1) | 11,329 (98.9) | 11,453 | 0.000*** | 5.245–7.539 | 6.288 |
| Thiazide group | 21 (0.2) | 8,568 (99.8) | 8,589 | 0.167 | 0.880–2.080 | 1.353 |
| Thiazide-like | 6 (0.2) | 2,709 (99.8) | 2,715 | 0.626 | 0.547–2.722 | 1.221 |
| Carbonic anhydrase inhibitors | 2 (0.3) | 637 (99.7) | 639 | 0.433 | 0.432–0.937 | 1.730 |
| Loop diuretics | 19 (0.2) | 12,403 (99.8) | 12,422 | 0.457 | 0.536–1.324 | 0.843 |
| Potassium sparing diuretics | 11 (0.2) | 6,687 (99.8) | 6,698 | 0.743 | 0.501–1.638 | 0.906 |
| Selective Alginine Vasopressin Receptor antagonist | 1 (2.0) | 48 (98) | 49 | 0.002** | 1.584–83.201 | 11.430 |
| DHPS, CCB | 50 (0.2) | 27,170 (99.8) | 27,220 | 0.922 | 0.766–1.342 | 1.014 |
| NH-PCCB | 15 (0.2) | 6,622 (99.8) | 6,637 | 0.390 | 0.975–1.629 | 1.249 |
| Atorvastatin | 60 (0.2) | 26,354 (99.8) | 26,414 | 0.000*** | 1.390–1.839 | 1.599 |

Values are presented as number (%). DHPS: dihydropyridines, CCB:calcium channel blocker, NHP: nondihydropyridines. \( *p < 0.05, **p < 0.01, ***p < 0.001 \).
Risk of Developing Rosacea in Chronic Systemic Diseases and Medications

Fig. 4. (A) Risk of diagnosed rosacea according to specific diuretics, (B) risk of diagnosed rosacea according to specific $\alpha$-blockers and $\beta$-blocker, classified drugs by subtypes. *$p<0.05$

with patients not taking them. When divided by sex, patients taking carbonic anhydrase inhibitors showed significantly increased tendency to develop rosacea only among male patients. In contrast, among patients taking V2 arginine vasopressin receptor antagonists, only female patients exhibited increased tendency to develop rosacea.

Risk of diagnosed rosacea according to gender

We divided into male and female, and find each increased odds ratio for rosacea development in patients with dyslipidemia (OR 1.718, 95% CI 1.170–2.523, $p=0.005$ for males and OR 1.843, 95% CI 1.427–2.381, $p<0.001$ for females). Also of interest, only female patients with diabetes mellitus (DM) (OR 3.260, 95% CI 1.350–7.870, $p=0.005$) and cerebral infarction (OR 0.413, 95% CI 0.197–0.868, $p=0.016$) showed increased and decreased tendency to develop rosacea. In the case of hypertension, only males showed an increased tendency to develop rosacea. For male patients with every prescribed drug mentioned above (except diuretics) showed a significantly increased tendency to develop rosacea. For female patients, only those with $\alpha$-blockers (OR 8.779, 95% CI 5.159–14.938, $p<0.001$) and BB (OR 4.813, 95% CI 4.026–5.752, $p<0.001$) prescriptions were more likely to have rosacea.

Risk of diagnosed rosacea according to chronic systemic diseases, as related to cardiovascular risk factors and prescribed drugs, after divided analysis of disease and drugs

Even when paired divided analyses were carried out with confounding factors, hypertension, dyslipidemia, BB showed significantly increased the tendency to develop rosacea.

On the other hand, among the patients who took HMG-CoA reductase inhibitor without dyslipidemia, rosacea was less likely to be diagnosed (OR 0.780, 95% CI 0.620–0.982, $p=0.034$) (Fig. 5, Table 4).

DISCUSSION

Reported incidence and prevalence of rosacea vary between countries, ranging from 0.06% to 22%3,9. Rosacea affects up to 15% of the general population of fair-skinned northern European heritage7. The overall incidence rate for diagnosed rosacea in the UK was 1.65/1,000 person-years. The prevalence of rosacea in the general population of Germany and Russia was 12.3% and 5.0%, respectively10. Rosacea seems relatively common among Caucasians and occurs less frequently in other ethnicities. In South Korea, Koo et al.11 (1997) studied 7,797 patients who visited a dermatology clinic for five years. Among these, 133 patients were diagnosed with rosacea; so the frequency of rosacea was 1.7%. In another study done by Kim et al.12, 8,491 patients who visited the department of dermatology were studied for two years, and 82 patients were diagnosed with rosacea, revealing the frequency of rosacea to be 0.97%. In our study, the frequency of rosacea over five years in our group of hospitals was 0.18%. The relatively low incidence may be due to a patient missing from the tertiary hospital. The study data included only patients who visited the five hospitals. There might be patients who did not come to dermatologists due to mild symptoms and signs13. Also, Korean people, most of whom are Asian, may have different prevalence rates11,12.

Our study confirmed a significant association of rosacea and dyslipidemia. There are some explanations about the association between hyperlipidemia and rosacea, such as
Fig. 5. Odds ratio for the risk of diagnosed rosacea in (A) total population, (B) males, and (C) females, after subdivided analysis. HMG-CoA: [beta]-hydroxy-[beta]-methylglutaryl coenzyme A, CVA: cerebrovascular attack, ASA: aspirin. *p<0.05.

A high rate of alcohol consumption and genetic factors; among other, unknown factors. Systemic inflammation can lead to structural changes in lipoproteins, negatively affecting their ability to remove cholesterol. In a case-control study of Duman et al., high total cholesterol (>200 mg/dl) and low-density lipoprotein cholesterol (>130 mg/dl) were significantly more common in the rosacea patients compared to controls. Rainer et al. also found a significant association between hyperlipidemia and rosacea in a skin severity-dependent manner in a case-control study (OR 6.8, 95% CI 1.900~24.600, p=0.003). For these reasons, chronic inflammation from rosacea could be the cause of frequent dyslipidemia. Antihyperlipidemic drugs, HMG-CoA reductase inhibitors
### Table 4. The risk of diagnosed rosacea according to chronic systemic diseases, which is related to cardiovascular risk factors and drugs after subdivided analysis

| Variable                              | Number of patients | Total population | OR   | 95% CI          | p-value | OR   | 95% CI          | p-value |
|---------------------------------------|--------------------|------------------|------|-----------------|---------|------|-----------------|---------|
| Diabetes                              | Rosacea, M/F       | Without rosacea, M/F | OR   | 95% CI          | p-value | OR   | 95% CI          | p-value |
| diabetes                              | 2 (0.3)/5 (0.8)    | 796 (99.8)/620 (99.2) | 2.724 | 1.295~5.730    | 0.006*  | 2.119 | 0.548~8.822     | 0.254   |
| Hypertension                          | 49 (0.3)/68 (0.2) | 28,002 (99.8)/27,165 (99.8) | 1.205 | 0.987~1.470     | 0.067   | 1.667 | 1.230~2.260     | 0.001** |
| Hypertension with BB                  | 9 (0.1)/13 (0.2)  | 6,183 (99.9)/5,777 (99.8) | 1.061 | 0.697~1.615     | 0.781   | 1.326 | 0.687~2.560     | 0.399   |
| Hypertension without BB               | 40 (0.2)/55 (0.3) | 21,819 (99.8)/21,388 (99.7) | 1.154 | 0.940~1.417     | 0.177   | 1.702 | 1.238~2.341     | 0.000*** |
| Hypertension with β-blocker           | 2 (0.3)/1 (0.5)   | 702 (99.7)/209 (99.5) | 1.900 | 0.611~5.906     | 0.212   | 2.592 | 0.401~6.826     | 0.182   |
| Hypertension without β-blocker        | 47 (0.2)/67 (0.2) | 27,300 (99.8)/26,956 (99.8) | 1.222 | 1.010~1.475     | 0.037*  | 1.601 | 1.191~2.151     | 0.002** |
| Hypertension with ASA                 | 8 (0.1)/16 (0.2)  | 8,753 (99.9)/7,757 (99.8) | 0.836 | 0.559~1.251     | 0.385   | 0.828 | 0.413~1.107     | 0.596   |
| Hypertension without ASA              | 41 (0.2)/52 (0.3) | 19,249 (99.8)/19,408 (99.7) | 1.403 | 1.140~1.726     | 0.001** | 1.988 | 1.451~2.274     | 0.000*** |
| Cerebral infarction                   | 14 (0.1)/29 (0.0) | 14,957 (99.9)/14,512 (100.0) | 0.431 | 0.244~0.760     | 0.003** | 0.516 | 0.214~1.243     | 0.133   |
| Cerebral infarction without ASA       | 10 (0.1)/19 (0.2) | 8,649 (99.9)/9,108 (99.8) | 0.957 | 0.664~1.381     | 0.816   | 1.051 | 0.563~1.962     | 0.876   |
| Dyslipidemia                          | 28 (0.2)/60 (0.4) | 14,444 (99.8)/14,297 (99.6) | 1.788 | 1.445~2.212     | 0.000*** | 1.718 | 1.170~2.523     | 0.005** |
| Dyslipidemia with HMG-CoA reductase inhibitor | 14 (0.2)/35 (0.4) | 8,124 (99.8)/7,779 (99.6) | 1.793 | 1.350~2.380     | 0.000*** | 1.576 | 0.928~2.675     | 0.089   |
| Dyslipidemia without HMG-CoA reductase inhibitor | 14 (0.2)/25 (0.4) | 6,520 (99.8)/6,518 (99.6) | 1.737 | 1.265~2.384     | 0.001** | 1.968 | 1.159~3.341     | 0.011*  |
| α-blocker                             | 10 (0.2)/2 (0.2)  | 4,321 (99.8)/853 (99.8) | 1.963 | 1.200~3.212     | 0.006** | 2.760 | 1.559~4.886     | 0.000*** |
| α-blocker without hypertension        | 8 (0.2)/1 (0.2)   | 3,619 (99.8)/645 (99.8) | 1.218 | 0.643~2.346     | 0.555   | 2.019 | 1.005~4.054     | 0.048*  |
| BB                                    | 58 (0.2)/163 (0.5) | 29,436 (99.8)/30,109 (99.5) | 5.106 | 4.380~5.953     | 0.000*** | 4.511 | 3.610~6.600     | 0.000*** |
| BB without hypertension               | 49 (0.2)/150 (0.6) | 23,251 (99.8)/24,333 (99.4) | 2.538 | 2.195~2.935     | 0.000*** | 1.977 | 1.480~2.641     | 0.000*** |
| HMG-CoA reductase inhibitor           | 51 (0.2)/73 (0.2) | 35,342 (99.8)/35,537 (99.8) | 1.599 | 1.390~1.839     | 0.000*** | 1.965 | 1.561~2.473     | 0.000*** |

Risk of Developing Rosacea in Chronic Systemic Diseases and Medications
and fibrates, showed significant association with increased diagnosis of rosacea. However, patients with dyslipidemia were significantly more likely to have rosacea; so interpretation should be careful. Interestingly, after subdivision, patients who were prescribed HMG-CoA reductase inhibitor but have no dyslipidemia showed less likely to have rosacea compared with those who were not prescribed HMG-CoA reductase inhibitor or have dyslipidemia. When divided into male and female, this result was not observed in male, but in female. This difference may be due to the distinct skin physiology in men and women and physiologic differences between male and female rosacea.

Regarding the HMG-CoA reductase inhibitor, statin; it is reported to be effective against many other dermatologic diseases including psoriasis, eczema, graft-versus-host disease, uremic pruritus, vitiligo, and hirsutism. Also, its topical forms are employed in the treatment of acne, seborrhea, rosacea, and rhinophyma. With immunomodulatory effects, its systemic anti-inflammatory action in inflammatory arthritis and allergic asthma has been demonstrated. Additionally, statin inhibits the expression and secretion of MMP-1,-2,-3 and -9 from vascular smooth muscle cells and macrophages, compared with fibrate (no inhibition). MMPs play a major role in remodeling the extracellular matrix and also in the etiopathogenesis of rosacea; so the protective effects of statin on developing rosacea in patients with hyperlipidemia should be considered. Because our results with or without dyslipidemia showed different results in the effect on incidence of rosacea, controlled experimental data will be needed.

Our study revealed that patients with hypertension were not likely to have rosacea. In Duman’s case-control study, regarding hypertension there was no significant difference between the rosacea group and control group. Otherwise, Rainer et al. revealed patients with rosacea were more likely to have hypertension with severity-dependent manner. Underlying inflammatory cytokines and metabolic, immune, and endocrine changes might provide explanations. In our study, patients taking β-blockers and patients with CCB, diuretics, angiotensin-converting-enzyme inhibitor (ACEi), and angiotensin II receptor blocker (ARB) did not show any significant tendency like reported in other studies. It is important to note that our study did not show any significant tendency for those taking BBs, which may indicate that BBs do not play a major role in the development of rosacea.

Table 4. Continued

| Variable | Number of patients | Total population | Male | Female |
|----------|--------------------|------------------|------|--------|
|          | Rosacea, M/F | Without rosacea, M/F | Rosacea, M/F | Total population, M/F (n) | OR | 95% CI | p-value | OR | 95% CI | p-value | OR | 95% CI | p-value |
| HMG-CoA reductase inhibitor without dyslipidemia | 37 (0.1)/38 (0.1) | 27,228 (99.9)/27,718 (99.9) | 27,265/27,756 | 0.780 | 0.620~0.982 | 0.034* | 1.246 | 0.895~1.734 | 0.192 | 0.572 | 0.414~0.789 | 0.000*** |
| ASA | 31 (0.2)/38 (0.1) | 19,988 (99.8)/17,676 (99.8) | 20,019/17,714 | 0.923 | 0.726~1.172 | 0.509 | 1.426 | 0.995~2.043 | 0.055 | 0.888 | 0.644~1.230 | 0.464 |
| ASA without cerebral infarction | 27 (0.2)/28 (0.2) | 16,623 (99.8)/14,690 (99.8) | 16,650/14,718 | 1.013 | 0.775~1.324 | 0.924 | 1.493 | 1.016~2.192 | 0.041* | 0.805 | 0.554~1.170 | 0.256 |
| ASA without hypertension | 23 (0.2)/22 (0.2) | 15,135 (99.8)/13,229 (99.8) | 15,158/13,251 | 1.231 | 0.917~1.654 | 0.167 | 1.392 | 0.919~2.109 | 0.117 | 0.701 | 0.460~1.069 | 0.099 |

Values are presented as number (%). M: male, F: female, OR: odds ratio, CI: confidence interval, BB: β-blocker, ASA: aspirin, HMG-CoA: 3-hydroxy-3-methylglutaryl coenzyme A. *p<0.05, **p<0.01, ***p<0.001.
mended as an off-label treatment for erythematotelangiectatic rosacea\(^a\). In some case-control research, ORs for incident rosacea slightly decreased among patients with BB\(^b\). Use of CCBs, by the way, is commonly discouraged in patients with rosacea because they are considered a trigger or exacerbating factor\(^c,d,e\). Associations between the risk of incident rosacea and such antihypertensive drugs have been reported recently\(^f\); however, the evidence is limited and still controversial\(^g,h\).

Our study shows patients with DM have a significantly higher probability of experiencing rosacea. However, Duman et al.\(^1\) showed there were no significant differences between rosacea group and control group in fasting blood glucose levels and DM. Meanwhile, Spoendlin et al.\(^30\) found rosacea cases and controls had recorded DM diagnoses revealing decreased ORs. This further decreased with increasing hemoglobin A1c values and disease duration. The underlying mechanism seems related to the degree of endothelial dysfunction and thus impaired vasodilation. Rosacea has a vasodilatory component whereas DM is associated with impaired vasodilation congruent with the degree of endothelial dysfunction\(^31\). These suggest a decreased rosacea risk in DM patients but some residual confounding or chance cannot entirely be ruled out.

The incidence rate of rosacea among ischemic stroke and hemorrhagic stroke patients was reported to be 1.19 and 1.11, respectively, but both were without statistical significance\(^32\). In our study, patients with cerebral infarction were statistically less prone to have rosacea. Meanwhile, aspirin slightly raised the OR in the male population without CVD. CVD is also associated with other risk factors or confounding factors, such as alcohol, smoking, and obesity, which are difficult to interpret. Not many studies on these have been reported and they are still controversial. As suggested mechanism, aspirin blocks synthesis of prostaglandin, which induces vasodilation\(^33,34\).

The limitations of this study are as follows. Firstly, this study included a population of patients who visited hospitals, not the general population. However, other cohort or case-control studies using national databases also included populations of patients who visited hospitals. Second, the records of ICD codes might be incomplete (e.g., many physicians might have forgotten to enter ICD codes and it might be possible that the diagnosis of specific disease has been included in the diagnosis for the insurance even without that disease. Because of those reasons, there may be missed cases. Also, here are limitations in that code may be entered for insurance claims. Therefore, it was not possible to exclude other inflammatory diseases. Additional case-control studies are needed. Also, in some cases, there may be use of preventive medicines used differently from the proposals of the National Health Insurance). Third, using the chi-square test, we could confirm the relations between each group due to limitations in the use of medical records. Later on, case-control study or cohort study with multiple logistic regression analysis would be needed to check the odd ratio or relative rate. Also, we could not check the exact date of occurrence of the disease or distinguish new patients from patients with existing disease. So, it is unclear whether rosacea would be the prodrome sign or one of the clinical feature/sequel of specific chronic systemic diseases, and rosacea can be regarded as one of drug side reaction. At last, because this study is limited to patients seen in a hospital setting, patients with more severe rosacea might be included. Also, in this study, we did not survey the general population and only studied patients who visited five hospitals, which are located locally in some urban areas. The selection of hospitals is not the probability allocation, so the data of five hospitals can not represent those of South Korea. Also, these data only showed not the prevalence of rosacea but the frequency of diagnosed rosacea. Due to these limitations, an interpretation will need to be careful. It might be thought to have only the significane as a preliminary experiment. In addition, it was hard to evaluate patients taking a combination of drugs in one pill, so we could not include antihypertensive combinations such as ACEi with CCB agents, ARB with CCB, and so on. Additional study with the number of prescriptions or dose amounts will also be needed. Also, classification of rosacea into subtypes, using clinical data, such as clinical picture or histopathology results, and consideration for the influencing factors, such as environment, temperature, patient’s age, occupation and habits, cosmetics and topical agent might be needed in future studies.

This study determined the correlation of chronic systemic disease and rosacea in South Korean patients. We also demonstrated associations between rosacea and drugs for risk factors of CVDs. Patients with hyperlipidemia, in particular, were more likely to have rosacea; and patients prescribed with HMG-CoA reductase inhibitor seemed less likely to have rosacea. These results provide good evidence for explanations about the potential of rosacea occurrence when prescribing medications to patients with chronic systemic disease.

**ACKNOWLEDGMENT**

This study was supported by grants of the National Research Foundation of Korea (NRF), funded by the Ministry of Science, ICT & Future Planning (NRF-
REFERENCES

1. Duman N, Erocy Evans S, Atakan N. Rosacea and cardiovascular risk factors: a case control study. J Eur Acad Dermatol Venereol 2014;28:1165-1169.
2. Rainer BM, Fischer AH, Luz Felipe da Silva D, Kang S, Chien AL. Rosacea is associated with chronic systemic diseases in a skin severity–dependent manner: results of a case-control study. J Am Acad Dermatol 2015;73:604-608.
3. Rueda LJ, Motta A, Pabón JG, Barona MI, Meléndez E, Orozco B, et al. Epidemiology of rosacea in Colombia. Int J Dermatol 2017;56:510-513.
4. Schwab WD, Sulk M, Seeliger S, Nowak P, Aubert J, Mess C, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Invest Dermatol Symp Proc 2011;15:53-62.
5. Mehta NN, Azfar RS, Shin DB, Neimann AL, Troxel AB, Gelfand JM. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J 2009;31:1000-1006.
6. Ozbalkan Z, Efe C, Cesar M, Ertex N, Nasiogrul N, Berneis K, et al. An update on the relationships between rheumatoid arthritis and atherosclerosis. Atherosclerosis 2010;212:377-382.
7. Itani S, Arabi A, Harb D, Hamzeh D, Kibbi AG. High prevalence of metabolic syndrome in patients with psoriasis in Lebanon: a prospective study. Int J Dermatol 2016;55:390-395.
8. Merticariu A, Marinescu L, Neanu C. Rosacea and its comorbidities. J Transl Med Res 2016;21:17-23.
9. Spoendlin J, Voegel JJ, Jick SS, Meier CR. Diabetes mellitus, antidiabetic drugs and the risk of developing rosacea. Pharmacoepidemiology and Drug Safety 2012;21:275-276.
10. Tan J, Schöfer H, Araviiskaia E, Audibert F, Kerrouche N, Berg M. Prevalence of rosacea in the general population of Germany and Russia - the RISE study. J Eur Acad Dermatol Venereol 2016;30:428-434.
11. Koo BS, Kwon HJ, Kim BC, Lee KS, Song JY. A clinical study of 133 patients with rosacea. Korean J Dermatol 1997;35:402-410.
12. Kim TH, Hwang SM, Lee WS, Ahn SK, Choi EH. A clinical study of rosacea. Korean J Dermatol 2000;38:583-588.
13. Kim MS, Kim BS, Koh WS, Lee SS, Seo SL, Chun DK, et al. Rosacea: clinical study of 67 cases. Ann Dermatol 2001;13:39-43.
14. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1135-1143.
15. Luebbenning S, Krueger N, Kerscher M. Skin physiology in men and women: in vivo evaluation of 300 people including TEWL, SC hydration, sebum content and skin surface pH. Int J Cosmet Sci 2013;35:477-483.
16. BORRIE P. Rosacea with special reference to its ocular manifestations. Br J Dermatol 1953;65:458-463.
17. Jowkar F, Namazi MR. Statins in dermatology. Int J Dermatol 2010;49:1235-1243.
18. Namazi MR. Statins: novel additions to the dermatologic arsenal? Exp Dermatol 2004;13:337-339.
19. McKay A, Leung BP, McNnies IB, Thomson NC, Liew FY. A novel anti-inflammatory role of simvastatin in a murine model of allergic asthma. J Immunol 2004;172:2903-2908.
20. Stoll LL, McCormick ML, Denning GM, Weintraub NL. Antioxidant effects of statins. Drugs Today (Barc) 2004;40:975-990.
21. Katsumoto M, Shingu T, Kuvashima R, Nakata A, Nomura S, Chayama K. Biphase effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis. Circ J 2005;69:1547-1555.
22. Luan Z, Chase AJ, Newby AC. Statins inhibit secretion of metalloproteinases-1,-2,-3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 2003;23:769-775.
23. Koh KK, Ahn JY, Jin DK, Han SH, Kim HS, Choi IS, et al. Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia. Int J Cardiol 2004;97:239-244.
24. Dollery CM, McEwan JR, Henney AM. Matrix metalloproteinases and cardiovascular disease. Circ Res 1995;77:863-868.
25. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002;90:251-262.
26. Odom R, Dahl M, Dover J, Draelos Z, Drake L, Maccain D, et al. Standard management options for rosacea, part 1: overview and broad spectrum of care. Cutis 2009;84:43-47.
27. Spoendlin J, Voegel J, Jick S, Meier CR. Antihypertensive drugs and the risk of incident rosacea. Br J Dermatol 2014;171:130-136.
28. Powell FC. Clinical practice. Rosacea. N Eng J Med 2005;352:793-803.
29. Natale F, Cirillo C, Granato C, Concilio C, Siciliano A, Credendino M, et al. Worsening of rosacea in patients treated with dihydropyridine calcium channel blockers: a clinical observation. Hypertens Res 2011;34:790-791.
30. Spoendlin J, Voegel JJ, Jick SS, Meier CR. Risk of rosacea in patients with diabetes using insulin or oral antidiabetic drugs. J Invest Dermatol 2013;133:2790-2793.
31. Browne D, Meeking D, Shaw K, Cummings M. Review: endothelial dysfunction and pre-symptomatic atherosclerosis in type 1 diabetes — pathogenesis and identification. Br J Diabetes Vasc Dis 2003;3:27-34.
32. Guerrera M, Parodi A, Cipriani C, Divano C, Rebora A. Flushing in rosacea: a possible mechanism. Arch Dermatol Res 1982;272:311-316.
33. Egeberg A, Hansen PR, Gislason GH, Thyssen JP. Assessment of the risk of cardiovascular disease in patients with rosacea. J Am Acad Dermatol 2016;75:336-339.

34. Vane JR, Botting RM. The mechanism of action of aspirin. Thromb Res 2003;110:255-258.